Brella SweatControl Patch
Commercial- Indications
- Primary axillary hyperhidrosis
Company intelligence / Profile preview
Candesant Biomedical
San Francisco, California, United Statescandesant.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Candesant Biomedical has developed the Brella® SweatControl Patch™, an FDA-cleared, non-invasive topical patch for adults with excessive sweating. Clinical studies have shown significant sweat reduction lasting up to two months after a single three-minute in-office application. The technology uses targeted alkali thermolysis to inactivate overactive sweat glands with minimal discomfort and no downtime. Two successful clinical studies demonstrated efficacy and safety.
- Therapeutic areas
- Dermatology
- Modalities
- DeviceNon-pharmacological therapy (topical patch)
- Industry
- Therapeutic Medical Devices
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Candesant Biomedical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Candesant Biomedical.